Welcome to our dedicated page for BOUNDLESS BIO SEC filings (Ticker: BOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Boundless Bio, Inc. filings document a clinical-stage oncology issuer focused on ecDNA-directed cancer therapeutics, with formal disclosures on operating results, research programs, and material events. Recent 8-K reports furnish quarterly and annual financial results and business updates for BBI-940, KOMODO-1, and the discontinued POTENTIATE program involving BBI-355 and BBI-825.
Its proxy and current reports also cover board composition, director elections, auditor ratification, stockholder voting results, and facility-related obligations, including lease-termination arrangements. These filings frame the company’s clinical-development disclosures, public-company governance, capital allocation, and operating obligations.
Form 4 Overview: On 06/23/2025, Boundless Bio, Inc. (ticker BOLD) filed a Form 4 disclosing a grant of derivative securities to director and 10% owner Kristina Burow.
- Security granted: Stock option (right to buy)
- Quantity: 16,000 options
- Exercise price: $1.03 per share
- Vesting schedule: Monthly over 12 months beginning 06/23/2025; any unvested portion accelerates to the next annual shareholder meeting if earlier.
- Expiration: 06/22/2035
- Ownership form after transaction: Direct (16,000 derivative securities)
No non-derivative share transactions were reported. The filing represents routine director compensation rather than an open-market purchase, and it does not include financial performance metrics or earnings data.
Boundless Bio director Nancy Whiting received a stock option grant on June 23, 2025, according to a Form 4 filing. The key details of the transaction include:
- Granted 16,000 stock options to purchase common stock
- Exercise price set at $1.03 per share
- Options expire on June 22, 2035
- Vesting schedule: Equal monthly installments over 12 months through June 23, 2026
- Accelerated vesting provision if next annual stockholder meeting occurs before June 23, 2026
The options were granted as part of director compensation and are subject to continued service on the company's board. The transaction was executed under direct ownership, with Jessica Oien signing as attorney-in-fact for Nancy Whiting.
Boundless Bio, Inc. (Nasdaq: BOLD) filed a Form 8-K detailing the results of its 23 June 2025 annual meeting of stockholders.
- Director elections: Class I nominees Christine Brennan, Ph.D. (9,252,440 for / 5,046,258 withheld) and Nancy Whiting, Pharm.D. (9,758,214 for / 4,540,484 withheld) were elected to serve until the 2028 annual meeting; 3,540,518 broker non-votes were recorded for each candidate.
- Auditor ratification: Shareholders ratified KPMG LLP as independent registered public accounting firm for fiscal 2025 with 17,791,309 votes for, 47,807 against and 100 abstentions.
No other matters were brought before shareholders and no additional material disclosures were made.